A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 110
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : PPPM
Long Form : per patient per month
No. Year Title Co-occurring Abbreviation
2001 Costs and resources associated with the treatment of overactive bladder using retrospective medical care claims data. OAB
2003 Evaluation of a monthly coverage maximum (drug-specific quantity limit) on the 5-HT1 agonists (triptans) and dihydroergotamine nasal spray. DHE, MCOs
2003 Impact of chronic kidney disease and anemia on hospitalization expense in patients with left ventricular dysfunction. ACE, CI, GFR, NYHA
2003 The changing direct costs of medical care for patients with HIV/AIDS, 1995-2001. HAART
2004 Cost analysis of a managed care decentralized outpatient pharmacy anticoagulation service. AF, INR, OPAS
2004 Effects of an increase in prescription copayment on utilization of low-sedating antihistamines and nasal steroids. LSAs, NSs, PMPM
2004 Severe sepsis in managed care: analysis of incidence, one-year mortality, and associated costs of care. IPA, MCO, SS
2005 Comparison of mental health resources used by patients with bipolar disorder treated with risperidone, olanzapine, or quetiapine. ---
2005 Hospital and outpatient health services utilization among HIV-infected adults in care 2000-2002. HAART
10  2005 Pharmacist response to alerts generated from Medicaid pharmacy claims in a long-term care setting: results from the North Carolina polypharmacy initiative. NC, PDTPs
11  2006 Assessment of clinical, service, and cost outcomes of a conversion program of sumatriptan to rizatriptan ODT in primary care patients with migraine headaches. ODT
12  2006 Per-patient-per-month drug costs in Medicare Part D protected classes. ---
13  2007 Actuarial analysis of private payer administrative claims data for women with endometriosis. ---
14  2007 Effect on drug utilization and expenditures of a cost-share change from copayment to coinsurance. OOP, PMPM
15  2008 Analysis of costs associated with administration of intravenous single-drug therapies in metastatic breast cancer in a U.S. population. CSFs, MBC, NCCN
16  2008 Assessing the economic burden of breast cancer in a US managed care population. ---
17  2008 Cost of medical care for HIV-infected patients within a regional population from 1997 to 2006. ART
18  2008 Humanistic, utilization, and cost outcomes associated with the use of botulinum toxin for treatment of refractory migraine headaches in a managed care organization. QOL
19  2008 Opioid drug utilization and cost outcomes associated with the use of buprenorphine-naloxone in patients with a history of prescription opioid use. DUE, MCO
20  2009 Cost implications of IV versus oral anti-angiogenesis therapies in patients with advanced renal cell carcinoma: retrospective claims database analysis. AI, RCC
21  2009 Direct all-cause health care costs associated with chronic kidney disease in patients with diabetes and hypertension: a managed care perspective. CKD
22  2009 Neutropenia-related costs in patients treated with first-line chemotherapy for advanced non-small cell lung cancer. CI, CIs, NSCLC, SD, SEER
23  2011 Comparison of healthcare costs between local and immigrant HIV populations living in Southern Alberta, Canada. IDU
24  2011 Determinants of medicare all-cause costs among elderly patients with renal cell carcinoma. RCC, SEER
25  2011 Economic impact of disease progression in follicular non-Hodgkin lymphoma. f-NHL, PD
26  2012 Costs and clinical outcomes among patients with second-line non-small cell lung cancer in the outpatient community setting. OS, PFS
27  2012 Costs associated with angiogenesis inhibitor therapies for metastatic renal cell carcinoma in clinical practice: results from a medical chart review study. AI, BEV, i.v, mo, SOR, SU
28  2012 Healthcare resource use in advanced prostate cancer patients treated with docetaxel. ER, mCRPC
29  2012 Impact of disease severity on healthcare costs in patients with chronic hepatitis C (CHC) virus infection. CC, CHC, ESLD, HCV, ICD-9, NCD
30  2012 Integrated complex care coordination for children with medical complexity: a mixed-methods evaluation of tertiary care-community collaboration. CMC, CSHCN
31  2012 Medical care costs and survival associated with hepatocellular carcinoma among the elderly. HCC, SEER
32  2012 The economic burden of metastatic breast cancer: a U.S. managed care perspective. ---
33  2013 Association between teriparatide adherence and healthcare utilization and costs in real-world US kyphoplasty/vertebroplasty patients. KV, PDC
34  2013 Costs Associated with Intravenous Cancer Therapy Administration in Patients with Metastatic Soft Tissue Sarcoma in a US Population. mSTS, PPPV
35  2013 Hepatitis C virus therapy is associated with lower health care costs not only in noncirrhotic patients but also in patients with end-stage liver disease. CC, ESLD, HCV, NCD
36  2013 Medical claim cost impact of improved diabetes control for medicare and commercially insured patients with type 2 diabetes. NHANES
37  2013 The burden of metastatic melanoma: treatment patterns, healthcare use (utilization), and costs. CR, LN
38  2014 Association between teriparatide adherence and healthcare utilization and costs among hip fracture patients in the United States. PDC, TPTD
39  2014 Comparison between guideline-preferred and nonpreferred first-line HIV antiretroviral therapy. ART, HIV, OR
40  2014 Diagnostic testing managed by hematopathology specialty and other laboratories: costs and patient diagnostic outcomes. BM, LL, OL
41  2014 Economic burden of brain metastases among patients with metastatic melanoma in a USA managed care population. ---
42  2014 Impact of early versus late systemic lupus erythematosus diagnosis on clinical and economic outcomes. RR, SLE
43  2014 Medicaid spending on contraceptive coverage and pregnancy-related care. LARC, OC, PFCPM, PMPM, SARC
44  2014 Resource utilization and cost in a commercially insured population with schizophrenia. ---
45  2014 The cost of antiretroviral drug resistance in HIV-positive patients. ARV, CDN, GART
46  2015 Cardiovascular event costs in patients with Type 2 diabetes mellitus. CVD, MACE, MI, T2DM
47  2015 Cardiovascular-related healthcare resource utilization and costs in patients with hypertension switching from metoprolol to nebivolol. CV, SD
48  2015 Comparison of Healthcare Costs Between Rheumatoid Arthritis Patients Treated with Infused Biologics After Switching from Another Biologic. anti-TNF, RA
49  2015 Costs, resource utilization, and treatment patterns for patients with metastatic melanoma in a commercially insured setting. MM
50  2015 Roflumilast: Who Is Using It and How It Affects Health Care Resource Utilization and Costs. COPD, HCRU
51  2016 Adherence to iron chelation therapy and associated healthcare resource utilization and costs in Medicaid patients with sickle cell disease and thalassemia. aIRR, ICT, MPR, SCD
52  2016 Budget Impact of Enzalutamide for Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer. CMS, mCRPC, PMPM, PPPY, SEER
53  2016 Characterizing downstream healthcare resource utilization and costs based on prior utilization patterns of immediate-release hydrocodone. ER, HRU, IR
54  2016 Comparison of medical costs and healthcare resource utilization of post-menopausal women with HR+/HER2- metastatic breast cancer receiving everolimus-based therapy or chemotherapy: a retrospective claims database analysis. AE, HRU, IRR, MBC
55  2016 Does Hepatitis C Treatment Adherence Affect Risk of Liver Transplantation? A Historical Cohort Study. HCV
56  2016 Effects of the prospective payment system on anemia management in maintenance dialysis patients: implications for cost and site of care. ESAs, ESRD, PPS
57  2016 Persistence, adherence, and all-cause healthcare costs in atazanavir- and darunavir-treated patients with human immunodeficiency virus in a real-world setting. ART, ATV, DRV, HIV, PDC
58  2016 Real-World Analysis of Medical Costs and Healthcare Resource Utilization in Elderly Women with HR+/HER2- Metastatic Breast Cancer Receiving Everolimus-Based Therapy or Chemotherapy. AE, HRU, MBC
59  2016 Treatment patterns and costs for anti-TNFalpha biologic therapy in patients with psoriatic arthritis. anti-TNFalpha, PsA
60  2017 A retrospective analysis of delays in the diagnosis of lung cancer and associated costs. NSCLC
61  2017 All-Cause, Stroke-, and Bleed-Specific Healthcare Costs: Comparison among Patients with Non-Valvular Atrial Fibrillation (NVAF) Newly Treated with Dabigatran or Warfarin. NVAF
62  2017 Comparison of treatment patterns and economic outcomes among metastatic pancreatic cancer patients initiated on nab-paclitaxel plus gemcitabine versus FOLFIRINOX. MPC
63  2017 Demographics, treatment patterns, and healthcare utilization and cost of repository corticotropin injection in patients with systemic lupus erythematosus or rheumatoid arthritis. HRU, RA, RCI, SLE
64  2017 Direct medical costs of treatment in newly-diagnosed high-grade glioma among commercially insured US patients. GBM, TMZ
65  2017 Evaluation of Patient Migration Patterns and Related Health Care Costs Within a National Medicare Advantage Prescription Drug Plan After Implementation of an Oxycodone HCl Extended-Release Access Restriction. OERs
66  2017 Healthcare Costs Among Patients with Heart Failure: A Comparison of Costs between Matched Decedent and Survivor Cohorts. HF, MAPD
67  2017 Healthcare utilization and costs for patients initiating Dabigatran or Warfarin. CI, ER, HCRU, HR, NOAC, NVAF
68  2017 Incidence of dose escalation and impact on biologic costs among patients with rheumatoid arthritis treated with three intravenous agents. ---
69  2017 Major bleeding risk and healthcare economic outcomes of non-valvular atrial fibrillation patients newly-initiated with oral anticoagulant therapy in the real-world setting. CI, HR, MB, NVAF, PSM
70  2017 Medical resource utilization in dermatomyositis/polymyositis patients treated with repository corticotropin injection, intravenous immunoglobulin, and/or rituximab. DM/PM, HOPD, IVIG, LOS, MRU, RCI
71  2017 Multidisciplinary intervention to improve albuterol inhaler utilization among patients with asthma. IQR
72  2017 Real-world costs and outcomes in metastatic renal cell carcinoma patients treated with targeted therapies: a cohort study from the French health insurance database. mRCC, NHI, OS, PFS
73  2017 Real-world Direct Health Care Costs for Metastatic Colorectal Cancer Patients Treated With Cetuximab or Bevacizumab-containing Regimens in First-line or First-line Through Second-line Therapy. 1L-2L, BEV, CET, CI, mCRC
74  2017 Real-World Treatment Patterns, Time to Next Treatment, and Economic Outcomes in Relapsed or Refractory Multiple Myeloma Patients Treated with Pomalidomide or Carfilzomib. ASCO, MM, TTNT
75  2017 Self-reported hypoglycemia in insulin-treated patients with diabetes: Results from an international survey on 7289 patients from nine countries. HAT, IO HAT
76  2018 All-Cause, Stroke/Systemic Embolism-, and Major Bleeding-Related Health-Care Costs Among Elderly Patients With Nonvalvular Atrial Fibrillation Treated With Oral Anticoagulants. MB, NVAF, OACs, SE
77  2018 An evaluation of warfarin use at an urban district-level hospital in KwaZulu-Natal Province, South Africa. IQR, SEM
78  2018 Burden of illness of chemotherapy in castration-resistant prostate cancer patients in Japan: a retrospective database analysis. CRPC, JPY
79  2018 Comparison of all-cause costs and healthcare resource use among patients with newly-diagnosed non-valvular atrial fibrillation newly treated with oral anticoagulants. HCRU, NVAF
80  2018 Cost analysis for different sequential treatment regimens for metastatic renal cell carcinoma in China. AEs, mRCC, PFS
81  2018 Cost Differences Associated With Oncology Care Delivered in a Community Setting Versus a Hospital Setting: A Matched-Claims Analysis of Patients With Breast, Colorectal, and Lung Cancers. SD
82  2018 Differences in All-Cause Health Care Utilization and Costs in a Type 2 Diabetes Mellitus Population with and Without a History of Cardiovascular Disease. CVD, EMR, ER, RR, T2DM
83  2018 Economic Burden Associated with Receiving Inhaled Corticosteroids with Leukotriene Receptor Antagonists or Long-Acting Beta Agonists as Combination Therapy in Older Adults. ICS, LABA, LTRA
84  2018 Economic burden of elderly patients with acute myeloid leukemia treated in routine clinical care in the United States. AML, HCU, ICU, SCT
85  2018 Economic Burden of HR+/HER2- Metastatic Breast Cancer Among Adult Premenopausal Women. ET, HRU, IP, MBC, OP, PPP6M
86  2018 Economic burden of multiple myeloma among patients in successive lines of therapy in the United States. MM
87  2018 Economic Burden of Patients Treated for Higher-Risk Myelodysplastic Syndromes (HR-MDS) in Routine Clinical Care in the United States. AML, HCU, HR-MDS, MDS, US
88  2018 Economic impact of preventing brain metastases with alectinib in ALK-positive non-small cell lung cancer. BM, CNS, NSCLC
89  2018 Health Care Costs of Anal Cancer in a Commercially Insured Population in the United States. HPV
90  2018 Health Care Resource Utilization and Costs Among Newly Diagnosed and Oral Anticoagulant-Naive Nonvalvular Atrial Fibrillation Patients Treated with Dabigatran or Warfarin in the United States. AF, HCRU, NVAF, OAC
91  2018 Health-care Cost Impact of Continued Anticoagulation With Rivaroxaban vsAspirin for Prevention of Recurrent Symptomatic VTE in the EINSTEIN-CHOICE Trial Population. ---
92  2018 Healthcare utilization and direct costs of non-infectious comorbidities in HIV-infected patients in the USA. CKD, CVD
93  2018 Incremental burden of type 2 diabetes in patients experiencing cardiovascular hospitalizations. CV, HCRU
94  2018 Newly Diagnosed Hepatitis C in the US Commercially Insured Population Before and After the 2012 Implementation of Expanded Screening Guidelines. HCV
95  2018 Postsurgical treatment landscape and economic burden of locoregional and distant recurrence in patients with operable nonmetastatic melanoma. HRU
96  2018 Real-world analysis of cost, health care resource utilization, and supportive care in Hodgkin lymphoma patients with frontline failure. FL, FLF, HL, RT
97  2018 Real-World Comparative Effectiveness, Safety, and Health Care Costs of Oral Anticoagulants in Nonvalvular Atrial Fibrillation Patients in the U.S. Department of Defense Population. DOACs, DoD, NVAF, OACs, SE
98  2018 Real-world outcomes in patients with chronic obstructive pulmonary disease initiating long-acting mono bronchodilator therapy. COPD, SABA, SAMA
99  2018 Real-world utilization of molecular diagnostic testing and matched drug therapies in the treatment of metastatic cancers. CT, ET, GMTT, UTT
100  2018 Survival Rates and Health Care Costs for Patients With Advanced Bladder Cancer Treated and Untreated With Chemotherapy. ---
101  2018 The Direct and Indirect Costs Associated With Overactive Bladder Within a Commercially-Insured Population in the United States. OAB, STD, US
102  2018 The economic burden of overactive bladder (OAB) and its effects on the costs associated with other chronic, age-related comorbidities in the United States. OAB
103  2018 Workforce Configurations to Provide High-Quality, Comprehensive Primary Care: a Mixed-Method Exploration of Staffing for Four Types of Primary Care Practices. PCPs
104  2019 Comparison of all-cause, stroke, and bleed-specific healthcare resource utilization among patients with non-valvular atrial fibrillation (NVAF) and newly treated with dabigatran or warfarin. HCRU, NVAF
105  2019 Cost differential of immuno-oncology therapy delivered at community versus hospital clinics. IO
106  2019 Cost of peripheral neuropathy in patients receiving treatment for multiple myeloma: a US administrative claims analysis. MM, PIs, PN
107  2019 Economic Burden of Illness in Adult Patients with Nocturia. HCRU
108  2019 Evaluation of Treatment Patterns and Costs in Patients with Prostate Cancer and Bone Metastases. ASCO, IQR, mCRPC, PC
109  2019 Health Care Resource Utilization and Costs in First-Line Treatments for Patients with Metastatic Melanoma in the United States. ED, HCRU, ORs
110  2019 Real-world treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriasis. MPR